Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
Lancet Gastroenterol HepatolJul 16, 2026 (epub)
Clinical ResearchGastroenterology
Walter Reinisch, David Stepek, Radoslaw Kempinski et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2b, multicenter, randomized, placebo-controlled trial evaluated the efficacy and safety of duvakitug in adults with moderately to severely active ulcerative colitis. Among patients receiving duvakitug, 36% in the 450 mg group and 48% in the 900 mg group achieved clinical remission at week 14, compared to 20% in the placebo group, indicating significant efficacy.
Key findings
- 36% of patients in the duvakitug 450 mg group achieved clinical remission at week 14.
- 48% of patients in the duvakitug 900 mg group achieved clinical remission at week 14.
- The posterior probability of superiority to placebo was >0.99 for the 900 mg group.
- Adverse event incidence was similar across duvakitug and placebo groups.
Why it matters
The findings suggest that duvakitug may be an effective treatment option for patients with moderately to severely active ulcerative colitis, particularly for those who have not responded to previous therapies. Understanding new treatment options is crucial for improving patient outcomes.